Harvard Bioscience (HBIO) Cash from Operations Growth (3y) (2013 - 2026)
Harvard Bioscience (HBIO) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 16.81% |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | -10.46% |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 16.21% |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 24.18% |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | - |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | -9.84% |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | -14.72% |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 13.75% |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | -5.42% |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn | -54.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -54.94% |
| Mar 31, 2026 | -33.24% |
| Dec 31, 2025 | -26.74% |
| Sep 30, 2025 | 18.65% |
| Jun 30, 2025 | 154.58% |
| Mar 31, 2025 | 51.88% |
| Dec 31, 2024 | 145.21% |
| Sep 30, 2024 | -8.46% |
| Jun 30, 2024 | -45.83% |
| Mar 31, 2024 | 10.60% |
| Dec 31, 2023 | 20.00% |
| Sep 30, 2023 | 39.77% |
| Jun 30, 2023 | 14.39% |
| Mar 31, 2023 | -14.22% |
| Dec 31, 2022 | 6.46% |
| Sep 30, 2022 | -40.99% |
| Jun 30, 2022 | -31.79% |
| Mar 31, 2022 | -44.03% |
| Dec 31, 2021 | -64.40% |
| Sep 30, 2021 | 22.79% |